Global COPD and Asthma Devices Market Size By Type (Metered Dose Inhalers (MDI), Drug Powder Inhalers (DPI)), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

lobal COPD and Asthma Devices Market Report Description

The Global COPD and Asthma Devices Market was valued at USD 41.2 billion in 2023 and is projected to reach USD 68.4 billion by 2031, growing at a CAGR of 6.7% during the forecast period (2023–2031). The rising prevalence of respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD) and asthma, coupled with increasing air pollution and tobacco consumption, is driving the demand for advanced therapeutic and diagnostic devices. Moreover, technological innovations, including smart inhalers and portable nebulizers, are enhancing treatment outcomes, contributing significantly to market growth.

Drivers:

1. Increasing Prevalence of Respiratory Diseases:

COPD and asthma are among the most common chronic diseases globally, affecting millions. The growing patient base, especially in urban areas with poor air quality, is driving the demand for respiratory support devices.

2. Technological Advancements in Inhalation Devices:

The development of smart inhalers and digitally integrated nebulizers is revolutionizing disease management by improving medication adherence, providing real-time monitoring, and enabling better physician-patient communication.

3. Rising Geriatric Population:

With age being a key risk factor for COPD and asthma, the aging global population significantly contributes to increased adoption of respiratory care devices.

Restraints:

1. High Costs of Advanced Devices:

While innovative devices enhance patient outcomes, their high costs can limit accessibility, particularly in low- and middle-income regions, hindering widespread market adoption.

2. Limited Awareness and Diagnosis in Emerging Markets:

In many developing regions, underdiagnosis and lack of awareness about respiratory diseases and their management tools limit market penetration.

Opportunity:

1. Expansion into Emerging Economies:

Emerging markets, such as India, Brazil, and Southeast Asian nations, are witnessing growing healthcare investments and awareness campaigns, creating a favorable environment for market growth.

2. Integration of AI and IoT in Respiratory Care:

The use of AI-powered monitoring and data analytics in inhalation devices is opening new avenues for personalized treatment, disease prediction, and preventive care.

Market by System Type Insights:

Based on system type, inhalers accounted for the largest market share in 2023. This includes both metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), widely used for quick and effective delivery of medication. The nebulizers segment, particularly portable variants, is expected to grow at a notable pace due to rising demand for home-based treatment solutions. The integration of connectivity features in inhalers is also driving innovation in this segment.

Market by End-use Insights:

Hospitals and clinics emerged as the leading end-use segment in 2023, accounting for over 40% of total revenue. The need for precise diagnosis and professional supervision drives demand in these settings. However, the homecare segment is witnessing rapid growth, supported by the rising preference for self-administration, cost savings, and the availability of user-friendly portable devices.

Market by Regional Insights:

North America dominated the COPD and asthma devices market in 2023, led by advanced healthcare infrastructure, high awareness levels, and the presence of leading market players. Asia-Pacific is projected to be the fastest-growing region, driven by a high prevalence of respiratory diseases, expanding healthcare access, and growing pollution levels in urban areas. Europe holds a substantial share as well, supported by favorable reimbursement policies and aging demographics.

Competitive Scenario:

Leading players in the global COPD and Asthma Devices Market include GlaxoSmithKline plc, Boehringer Ingelheim GmbH, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Koninklijke Philips N.V., ResMed Inc., Omron Healthcare Inc., and Cipla Ltd. These companies are focusing on product innovation, strategic collaborations, and geographic expansion.

In 2023, Teva Pharmaceuticals launched a next-generation DPI with integrated adherence monitoring features.

Philips introduced a smart nebulizer system capable of syncing with mobile health apps in 2024.

In 2025, Cipla partnered with health tech startups to enhance real-time tracking and data analytics for respiratory devices.

Scope of Work – Global COPD and Asthma Devices Market

Report Metric Details

Market Size (2023) USD 41.2 billion

Projected Market Size (2031) USD 68.4 billion

CAGR (2023–2031) 6.7%

Market Segments By System Type (Inhalers, Nebulizers, Others), By End-use (Hospitals & Clinics, Homecare, Others), By Region

Growth Drivers Rising prevalence of COPD & asthma, aging population, technological advancements

Opportunities AI and IoT integration, expansion in emerging markets

Key Market Developments:

2023: GlaxoSmithKline launched a dual-action inhaler with improved patient usability.

2024: ResMed expanded its cloud-connected respiratory care platform for enhanced remote monitoring.

2025: AstraZeneca collaborated with digital health firms to develop AI-integrated asthma management solutions.

FAQs:

1) What is the current market size of the Global COPD and Asthma Devices Market?

The market was valued at USD 41.2 billion